Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$63.73M$63.73M+100.1% vs Q3 2016 Net Income$2.75M$2.75MN/M vs Q3 2016 EPS Diluted$20.00$20.00N/M vs Q3 2016 Gross Profit$5,257,000+25.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived$20,259,000N/M Free Cash Flowderived$20,098,000N/M Margins · derivedGross margin8.2%−4.9 pt vs Q3 2016
Operating margin12.7%+84.1 pt vs Q3 2016
Net margin4.3%+95.2 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 7, 2017 · 38 d after period end